En español
NIDA

Search

Menu

Women & Sex/Gender Differences Research Group

What We Do:

The mission of the Women and Gender Research Group is to promote the conduct, translation, and dissemination of drug abuse research on gender differences and issues specific to women. More information on Women's health available on the Women & Sex/Gender Differences Research Program pages.

Members:

Center for the Clinical Trials Network (CCTN)

  • Petra Jacobs, M.D. - (301) 496-8974 - clinical research and substance abuse treatment
  • Carmen L. Rosa, M.S. - (301) 443-9830 - clinical research/clinical trials; regulatory affairs; health disparities/ethnic populations; women's health; and criminal justice
  • Betty Tai, M.D. - (301) 443-6697 - clinical pharmacology; clinical trials relevant to clinical practice

Division of Basic Neuroscience & Behavioral Research (DBNBR)

  • Beth Babecki, M.A. - (301) 435-0899 - training and career development
  • Jerry Frankenheim, Ph.D. - (301) 435-1312 - neuroplasticity and neurotoxicology; methamphetamine and MDMA; marijuana; hallucinogens
  • Samia Noursi, Ph.D. - (301) 594-5622 - sex/gender differences; women's health; children's social and emotional development; child maltreatment; domestic violence
  • Vishnudutt Purohit, DVM, Ph.D. - (301) 594-5753 - prenatal and perinatal exposure of drugs; HIV/AIDS and HCV basic research; cardiovascular and hepatotoxicity; oxidative stress, inflammation, and apoptosis; epithelial and endothelial barriers, including blood brain barrier
  • Joni Rutter, Ph.D. - (301) 443-1887 - genetics
  • Cora Lee Wetherington, Ph.D. - (301) 435-1319 - basic behavioral laboratory research (animals and humans); prenatal drug exposure; sex/gender differences; vulnerability

Division of Clinical Neuroscience and Behavioral Research (DCNBR)

  • Jessica Campbell Chambers, Ph.D. - (301) 443-2237 - adolescent and family behavioral treatment
  • Joe Frascella, Ph.D. - (301) 443-4877 - clinical neurobiology; human neuroscience
  • Debbie Grossman, M.A. - (301) 443-0107 - smoking cessation treatment for adults and adolescent; marijuana dependence treatment for adults; treatment for cognitively impaired drug users
  • Mary Kautz, Ph.D., - 301-443-3206 - Neuropsychopharmacology, Human Behavioral Psychopharmacology, Smoking
  • Lisa Onken, Ph.D. - (301) 443-2235 - combined behavioral and pharmacological TX; stages of behavioral treatment (TX) research; treatment of co morbid psychiatric disorders and drug abuse; mechanism of action of behavioral treatment
  • Cece McNamara Spitznas, Ph.D. - (301) 402-1488 - treatment for stimulant & opioid abuse; integrating technology with treatment; therapist training and clinical supervision; behavioral, interpersonal, and psychotherapeutic approaches to change; HIV risk reduction

Division of Epidemiology, Services and Prevention Research (DESPR)

  • Redonna K. Chandler, Ph.D. - (301) 443-6504 - criminal justice; gender differences; co-occurring disorders
  • Dionne J. Jones, Ph.D. - (301) 402-1984 - interventions and treatment services for HIV/AIDS; gender differences; co-occurring disorders; ethnic populations (african american)
  • Elizabeth Lambert, M.Sc. - (301) 402-1933 - natural history and epidemiology of HIV/AIDS among drug users; HIV/AIDS and drug abuse; clinical epidemiology and HIV disease
  • Jacqueline Lloyd, Ph.D. - (301) 443-8892 - drug abuse prevention interventions; HIV prevention in at risk populations; peer and social network prevention interventions; role of family and peer factors on adolescent drug use
  • Marsha Lopez, Ph.D. - (301) 443-6504 - epidemiology of drug use and disorder; comorbidity of drug and other psychiatric disorders; national studies examining the patterns of drug use and disorder across the life course; research training

Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA)

  • Kris Bough, Ph.D., 301-443-9800 - smoking cessation treatment, clinical drug development, neuroscience
  • Jag H. Khalsa, Ph.D. - (301) 443-2159 - medical consequences of drugs of abuse and co-occurring infections including HIV, Hepatitis C, STDs, TB and others
  • Amrat P. Patel, Ph.D. - (301) 443-8476 - molecular pharmacology; medications development; pharmacokinetics

Office of Extramural Affairs (OEA)

  • Teri Levitin, Ph.D. - (301) 443-2755 - NIH and NIDA extramural policies and procedure; including grant review

Office of Science Policy and Communications (OSPC)

  • Ericka M. Boone, Ph.D. - (301) 443-6036 - social neuroscience; psychopharmacology; basic behavioral laboratory research; research training
  • Elizabeth Davis, M.P.H. - (301) 594-6317 - adolescent behavior; community-based research; public health
  • Jennifer Elcano, M.A. - (301) 594-6314 - science writing; prescription drugs; gender differences; pharmacotherapies
  • Carol Krause, M.A. - (301) 594-6148 - public education and outreach; media; web content; social marketing
  • Susan Weiss, Ph.D. - (301) 443-6071 - science policy and research; training

Office of the Director

  • Ana Anders - (301) 443-0441 - ethnic populations populations (hispanic-latino and asian american and pacific islander)
  • Katherine Davenny, M.P.H. - (301) 443-2146 - HIV/AIDS & other infectious diseases; medical consequences; medical/prevention interventions; mother-infant transmission; cross-NIH collaborations
  • Lynda Erinoff, Ph.D. - (301) 402-1972 - pharmacology; neuroscience; AIDS
  • Denise Pintello, Ph.D., M.S.W. - (301) 594-6316 - gender differences; sexual abuse and trauma; child maltreatment; child and adolescent development
  • Dale Weiss - (301) 443-6036 - international research collaboration; international research training; international research funding

Contact:

Any questions or concerns regarding the Women and Gender Research Group please contact Cora Lee Wetherington, Ph.D. (301) 435-1319 or wetherington@nih.gov and/or Samia Dawud Noursi, Ph.D. (301) 594-5622.

This page was last updated May 2012

    Featured Publication

    Featured Publication

    Drugs, Brains, and Behavior - The Science of Addiction

    As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.